Contributions
Abstract: PB2170
Type: Publication Only
Background
ENDEAVOR demonstrated superior response rates, depth of response, PFS, and OS with Kd56 vs Vd (bortezomib-dexamethasone).
Aims
Here, we assessed post-hoc the association between response and clinical outcomes/QoL.
Methods
Results
In the Kd56 arm, 77% of patients (pts) had a response: 13% ≥complete response (CR), 42% very good partial response (VGPR), and 22% PR. In pts at risk at the 2-mo landmark, median PFS beyond the landmark was not estimable (NE; 95% CI: 20.2, NE) in responders vs 10.9 mos (95% CI: 7.6, NE) in non-responders. Median OS beyond the landmark was 49.3 mos (95% CI: 45.6, NE) in responders vs 25.8 mos (95% CI: 19.8, 32.9) in non-responders. Simon-Makuch analysis indicated a significant difference in PFS and OS between responders and non-responders (p<0.001). For ≥CR, VGPR, or PR, median PFS (95% CI) was NE (NE, NE), 22.2 (18.7, NE), and 10.3 (8.8, 14.9) mos, respectively. Median OS (95% CI) was NE (NE, NE) for ≥CR, 51.3 (NE, NE) for VGPR, and 42.5 (33.6, 47.6) mos for PR. Kd56 responders had improved GHS/QoL scores vs Kd56 non-responders (difference in mean change [diff]: 7.22 [95% CI: −0.68, 15.12]). Among Kd56 responders, changes were similar by response depth (diff for ≥CR vs VGPR: 0.35; ≥CR vs PR: 1.59).
Conclusion
In the Kd56 arm, 77% of pts had a response and OS beyond the 2-mo landmark improved by 24 mos vs non-responders. Responders also had better GHS/QoL scores vs non-responders.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Multiple Myeloma, Proteasome inhibitor, Quality of Life, Survival
Abstract: PB2170
Type: Publication Only
Background
ENDEAVOR demonstrated superior response rates, depth of response, PFS, and OS with Kd56 vs Vd (bortezomib-dexamethasone).
Aims
Here, we assessed post-hoc the association between response and clinical outcomes/QoL.
Methods
Results
In the Kd56 arm, 77% of patients (pts) had a response: 13% ≥complete response (CR), 42% very good partial response (VGPR), and 22% PR. In pts at risk at the 2-mo landmark, median PFS beyond the landmark was not estimable (NE; 95% CI: 20.2, NE) in responders vs 10.9 mos (95% CI: 7.6, NE) in non-responders. Median OS beyond the landmark was 49.3 mos (95% CI: 45.6, NE) in responders vs 25.8 mos (95% CI: 19.8, 32.9) in non-responders. Simon-Makuch analysis indicated a significant difference in PFS and OS between responders and non-responders (p<0.001). For ≥CR, VGPR, or PR, median PFS (95% CI) was NE (NE, NE), 22.2 (18.7, NE), and 10.3 (8.8, 14.9) mos, respectively. Median OS (95% CI) was NE (NE, NE) for ≥CR, 51.3 (NE, NE) for VGPR, and 42.5 (33.6, 47.6) mos for PR. Kd56 responders had improved GHS/QoL scores vs Kd56 non-responders (difference in mean change [diff]: 7.22 [95% CI: −0.68, 15.12]). Among Kd56 responders, changes were similar by response depth (diff for ≥CR vs VGPR: 0.35; ≥CR vs PR: 1.59).
Conclusion
In the Kd56 arm, 77% of pts had a response and OS beyond the 2-mo landmark improved by 24 mos vs non-responders. Responders also had better GHS/QoL scores vs non-responders.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Multiple Myeloma, Proteasome inhibitor, Quality of Life, Survival